Cargando…
Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program
INTRODUCTION: Despite vaccination, there were more than 100,000 annual cases of varicella in the United States in 2013–2014. Individuals at highest risk of developing severe or complicated varicella include immunocompromised people, preterm infants, and pregnant women. Varicella zoster immune globul...
Autores principales: | Levin, Myron J., Duchon, Jennifer M., Swamy, Geeta K., Gershon, Anne A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608934/ https://www.ncbi.nlm.nih.gov/pubmed/31269033 http://dx.doi.org/10.1371/journal.pone.0217749 |
Ejemplares similares
-
Safety and Varicella Outcomes in In Utero–Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program
por: Duchon, Jennifer M, et al.
Publicado: (2019) -
2479. Varicella Zoster Immune Globulin Is Effective up to 10 Days Following Varicella Exposure in Pregnant Women, Immunocompromised Patients, and Infants: Results From a Large, Open-Label Expanded-Access Program
por: Levin, Myron, et al.
Publicado: (2018) -
Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program
por: Gans, Hayley, et al.
Publicado: (2021) -
Preventing varicella zoster infection in immunocompromised adults with varicella zoster–specific immunoglobulins
por: Gelman, Daniel, et al.
Publicado: (2023) -
Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster
por: Gershon, Anne A, et al.
Publicado: (2021)